Canada
· Delayed Price · Currency is CAD NexgenRx Statistics
Total Valuation
NexgenRx has a market cap or net worth of CAD 25.60 million. The enterprise value is 25.86 million.
| Market Cap | 25.60M |
| Enterprise Value | 25.86M |
Important Dates
The next estimated earnings date is Monday, August 18, 2025.
| Earnings Date | Aug 18, 2025 |
| Ex-Dividend Date | Apr 25, 2025 |
Share Statistics
NexgenRx has 71.12 million shares outstanding. The number of shares has increased by 9.69% in one year.
| Current Share Class | 71.12M |
| Shares Outstanding | 71.12M |
| Shares Change (YoY) | +9.69% |
| Shares Change (QoQ) | +8.87% |
| Owned by Insiders (%) | 37.18% |
| Owned by Institutions (%) | n/a |
| Float | 44.38M |
Valuation Ratios
The trailing PE ratio is 68.65.
| PE Ratio | 68.65 |
| Forward PE | n/a |
| PS Ratio | 1.52 |
| PB Ratio | 3.15 |
| P/TBV Ratio | 8.17 |
| P/FCF Ratio | 13.28 |
| P/OCF Ratio | 12.62 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 16.81, with an EV/FCF ratio of 13.42.
| EV / Earnings | 53.57 |
| EV / Sales | 1.54 |
| EV / EBITDA | 16.81 |
| EV / EBIT | 20.40 |
| EV / FCF | 13.42 |
Financial Position
The company has a current ratio of 1.12, with a Debt / Equity ratio of 0.06.
| Current Ratio | 1.12 |
| Quick Ratio | 0.12 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | 0.33 |
| Debt / FCF | 0.26 |
| Interest Coverage | 39.77 |
Financial Efficiency
Return on equity (ROE) is 8.31% and return on invested capital (ROIC) is 9.13%.
| Return on Equity (ROE) | 8.31% |
| Return on Assets (ROA) | 2.56% |
| Return on Invested Capital (ROIC) | 9.13% |
| Return on Capital Employed (ROCE) | 14.83% |
| Revenue Per Employee | 840,895 |
| Profits Per Employee | 24,141 |
| Employee Count | 20 |
| Asset Turnover | 0.54 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, NexgenRx has paid 412,150 in taxes.
| Income Tax | 412,150 |
| Effective Tax Rate | 37.71% |
Stock Price Statistics
The stock price has increased by +21.43% in the last 52 weeks. The beta is 0.77, so NexgenRx's price volatility has been lower than the market average.
| Beta (5Y) | 0.77 |
| 52-Week Price Change | +21.43% |
| 50-Day Moving Average | 0.30 |
| 200-Day Moving Average | 0.28 |
| Relative Strength Index (RSI) | 82.83 |
| Average Volume (20 Days) | 15,665 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NexgenRx had revenue of CAD 16.82 million and earned 482,829 in profits. Earnings per share was 0.01.
| Revenue | 16.82M |
| Gross Profit | 13.34M |
| Operating Income | 1.27M |
| Pretax Income | 1.09M |
| Net Income | 482,829 |
| EBITDA | 1.44M |
| EBIT | 1.27M |
| Earnings Per Share (EPS) | 0.01 |
Balance Sheet
The company has 1.90 million in cash and 507,860 in debt, giving a net cash position of 1.39 million or 0.02 per share.
| Cash & Cash Equivalents | 1.90M |
| Total Debt | 507,860 |
| Net Cash | 1.39M |
| Net Cash Per Share | 0.02 |
| Equity (Book Value) | 8.12M |
| Book Value Per Share | 0.09 |
| Working Capital | 2.93M |
Cash Flow
In the last 12 months, operating cash flow was 2.03 million and capital expenditures -101,263, giving a free cash flow of 1.93 million.
| Operating Cash Flow | 2.03M |
| Capital Expenditures | -101,263 |
| Free Cash Flow | 1.93M |
| FCF Per Share | 0.03 |
Margins
Gross margin is 79.34%, with operating and profit margins of 7.54% and 4.05%.
| Gross Margin | 79.34% |
| Operating Margin | 7.54% |
| Pretax Margin | 6.50% |
| Profit Margin | 4.05% |
| EBITDA Margin | 8.56% |
| EBIT Margin | 7.54% |
| FCF Margin | 11.46% |
Dividends & Yields
This stock pays an annual dividend of 0.01, which amounts to a dividend yield of 2.78%.
| Dividend Per Share | 0.01 |
| Dividend Yield | 2.78% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 133.40% |
| Buyback Yield | -9.69% |
| Shareholder Yield | -6.71% |
| Earnings Yield | 1.89% |
| FCF Yield | 7.53% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
NexgenRx has an Altman Z-Score of 1.12 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.12 |
| Piotroski F-Score | 7 |